Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)
Free GMTX Stock Alerts
$32.18
+0.26 (+0.81%)
(As of 05/17/2024 ET)
Compare
Today's Range
$31.44
▼
$32.48
50-Day Range
$13.50
▼
$67.64
52-Week Range
$1.16
▼
$14.10
Volume
376,433 shs
Average Volume
189,291 shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
GMTX stock logo

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

GMTX Stock Price History

GMTX Stock News Headlines

April 17, 2024 | seekingalpha.com
Google's public release of Gemini 1.5 should build trust, Deutsche Bank says
February 26, 2024 | washingtonpost.com
Google takes down Gemini AI image generator. Here’s what you need to know.
February 26, 2024 | nypost.com
‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasco
June 24, 2023 | benzinga.com
(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson Fistel
June 1, 2023 | barrons.com
Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
January 13, 2023 | markets.businessinsider.com
The Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalates
January 1, 2023 | usatoday.com
Gemini Horoscope
December 27, 2022 | finance.yahoo.com
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria
October 31, 2022 | finance.yahoo.com
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)
September 27, 2022 | benzinga.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTX
September 26, 2022 | benzinga.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
September 16, 2022 | markets.businessinsider.com
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZ
September 6, 2022 | markets.businessinsider.com
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFE
August 25, 2022 | apnews.com
The M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTX
August 24, 2022 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing Investigations
August 12, 2022 | apnews.com
GEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the Firm
August 12, 2022 | marketwatch.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. Merger
August 11, 2022 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.
August 11, 2022 | apnews.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
August 11, 2022 | apnews.com
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
August 10, 2022 | apnews.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)
August 10, 2022 | finance.yahoo.com
Blood disorder startup goes public by merging with embattled biotech
August 10, 2022 | seekingalpha.com
Gemini stock soars 35% on merger with Disc Medicine in all-stock deal
August 10, 2022 | nasdaq.com
Gemini Therapeutics, Disc Medicine Announce All-stock Merger
August 10, 2022 | finance.yahoo.com
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
See More Headlines

Company Calendar

Last Earnings
11/15/2021
Today
5/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GMTX
CUSIP
N/A
CIK
1816736
Web
www.geminitherapeutics.com
Phone
415-877-4887
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,870,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.78%
Return on Assets
-35.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
71.49
Quick Ratio
71.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
43,328,000
Free Float
37,739,000
Market Cap
$58.49 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

Key Competitors

View All Competitors

GMTX Stock Analysis - Frequently Asked Questions

How have GMTX shares performed in 2024?

Gemini Therapeutics' stock was trading at $57.76 at the beginning of 2024. Since then, GMTX stock has decreased by 44.3% and is now trading at $32.18.
View the best growth stocks for 2024 here.

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) issued its earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMTX) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
"The Biggest Drug Ever" Is Coming
Behind the Markets
Most important medical advance in 100 years
The Oxford Club
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star